Sidewinder Therapeutics Secures $137 Million Series B to Advance Precision Bispecific ADCs into Clinical Development for Cancer
Sidewinder Therapeutics, a biopharmaceutical company focused on advancing next-generation antibody-drug conjugates (ADCs) for oncology, has announced the successful closing of an oversubscribed $137 million Series B financing round. The capital raise represents a significant milestone for the company as it continues to build out its pipeline of bispecific ADC candidates designed to address difficult-to-treat cancers with high unmet medical need.
The Series B financing was co-led by Frazier Life Sciences and Novartis Venture Fund. The round also included participation from Sidewinder’s sole Series A investor OrbiMed, along with several new institutional investors. These new participants include Goldman Sachs Alternatives, DCVC Bio, Samsara BioCapital, Longwood Fund, Astellas Venture Management, and Alexandria Venture Investments.
In conjunction with the financing, Sidewinder Therapeutics has expanded its leadership oversight by appointing several representatives from its investor syndicate to its Board of Directors. Newly appointed board members include Daniel Estes, Ph.D. from Frazier Life Sciences, Michal Silverberg from Novartis Venture Fund, Josh Richardson, M.D. from Goldman Sachs Alternatives, and John Hamer, Ph.D. from DCVC Bio. Their combined experience across biotechnology investment, clinical development, and company building is expected to support Sidewinder’s strategic and operational growth as it advances its pipeline toward the clinic.
Eric Murphy, Ph.D., Co-Founder and Chief Executive Officer of Sidewinder Therapeutics, emphasized the significance of the financing round and the strength of the investor syndicate. He noted that the strong participation and oversubscription reflect broad confidence in the company’s scientific approach and long-term vision. According to Murphy, the antibody-drug conjugate field is currently undergoing a period of rapid transformation, driven by advances in molecular engineering and targeted delivery technologies. These innovations are enabling the development of more sophisticated ADC modalities, including bispecific constructs that can improve precision and therapeutic performance.
Sidewinder’s core platform is centered on the design and development of bispecific ADCs that target receptor co-complexes expressed on the surface of tumor cells. Unlike traditional monoclonal ADC approaches that bind to a single antigen, Sidewinder’s technology leverages internally discovered antibody sequences engineered to recognize two distinct receptors simultaneously. These receptors typically include an oncogenic driver receptor paired with an internalizing receptor, forming a co-complex that is selectively enriched on tumor cells.
This dual-targeting strategy is intended to improve tumor selectivity while enhancing internalization of the ADC payload into cancer cells. By precisely engaging receptor co-complexes that are preferentially expressed in malignant tissue, the platform aims to increase drug delivery efficiency while minimizing off-target toxicity in healthy tissues. This approach could potentially address some of the key limitations associated with first-generation ADCs, including suboptimal therapeutic windows and dose-limiting toxicities.
The company is applying its bispecific ADC platform across multiple oncology indications characterized by limited treatment options and significant disease burden. These include squamous cell carcinomas of the lung and head and neck, as well as gastrointestinal malignancies such as colorectal cancer. These tumor types often exhibit heterogeneous antigen expression and resistance to existing therapies, making them attractive targets for innovative treatment modalities that can enhance specificity and potency.
Sidewinder Therapeutics plans to utilize the proceeds from the Series B financing to advance its pipeline, further develop its proprietary platform, and support preclinical and translational research activities. The company has indicated that its lead program is expected to progress into clinical development by 2027, marking a key inflection point in its development trajectory. Achieving clinical-stage status will allow the company to begin evaluating safety, tolerability, pharmacokinetics, and early signs of efficacy in human patients.
In addition to pipeline advancement, the funding will likely support expansion of the company’s internal capabilities, including research and development infrastructure, manufacturing strategy, and regulatory planning. As ADCs are complex biologic therapeutics that require precise conjugation chemistry and rigorous quality control, investments in scalable manufacturing and analytical characterization are critical components of successful clinical translation.
Investors participating in the round highlighted the differentiation of Sidewinder’s scientific approach as a key factor underpinning their decision to invest. Daniel Estes, Ph.D., General Partner at Frazier Life Sciences, remarked that the company’s platform is built on compelling science and represents a differentiated strategy within the ADC landscape. He suggested that Sidewinder’s bispecific ADC pipeline has the potential to overcome longstanding challenges related to safety and efficacy that have historically limited broader adoption of this therapeutic class.
The ADC field has experienced notable momentum in recent years, with multiple approvals and a growing number of candidates advancing through clinical development. However, challenges remain in optimizing tumor selectivity, reducing systemic toxicity, and expanding the range of targetable antigens. Sidewinder’s bispecific approach seeks to address these issues by incorporating additional layers of molecular recognition, potentially enabling more precise targeting of tumor-specific biology.
As the company moves forward, its progress will be closely watched by industry stakeholders, particularly given the increasing interest in next-generation ADC modalities and multi-specific biologics. The combination of strong financial backing, experienced leadership, and a differentiated scientific platform positions Sidewinder Therapeutics to contribute to the evolving landscape of targeted cancer therapies.
With the closing of its Series B financing, Sidewinder enters a new phase of development, focused on translating its platform from discovery into clinical validation. The coming years will be critical in determining the therapeutic potential of its bispecific ADC approach and its ability to address some of the most challenging cancers facing patients today.
About Sidewinder Therapeutics
Sidewinder Therapeutics is developing next-generation bispecific ADCs designed to expand the therapeutic window through enhanced tumor specificity and internalization. The company has partnered with Lonza to apply Synaffix’s site-specific linker-payload platform across multiple programs. Founded in 2023 with OrbiMed, Sidewinder is headquartered in San Diego and has raised a total of $162 million from a world-class investor syndicate.
Source Link:https://www.businesswire.com/
